MONTREAL, Canada I September 26, 2014 I AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, the AVEO research was selected for presentation in an oral session titled “Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia.”
“These data expand our understanding of the central role that GDF15 may play in the development and progression of cancer cachexia,” said Jeno Gyuris, Ph.D., chief scientific officer of AVEO. “These studies demonstrate that elevated levels of circulating GDF15 drive the development of cancer cachexia in mice, and that its inhibition, with AV-380, completely reversed body weight loss and restored normal body composition, including fat, muscle and organ size. We have also demonstrated that the combination of AV-380, an anti-cachexia agent, with an anti-cancer treatment, dramatically prolonged survival compared to mice treated with anti-cancer therapy alone. We look forward to building on these discoveries as we progress AV-380 toward clinical study, expected to begin in the second half of 2015.”
“Cachexia is a well-recognized unmet medical need associated with multiple chronic disease states, including cancer, and is gaining increasing therapeutic focus, as noted in international scientific meetings such as the concurrent Cancer Cachexia Conference and European Society of Medical Oncology 2014 Congress,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “GDF15 may represent an important mechanism to target for therapeutic intervention, a hypothesis supported by selection of AVEO’s data for oral presentation by the Cancer Cachexia Conference.”
Data from these posters, titled “Induction of Cancer Cachexia by Inflammatory Molecules in Directed Complementation Tumor Models;” “Complete reversal of CASC in animal models by AV-380, a GDF15 inhibitory antibody;” “The combination of GDF15 blockade with an anti-cancer agent reverses cachexia and significantly prolongs survival in xenograft models;” and “Recombinant GDF15 does not trigger canonical SMAD2 pathway activation in vitro,” together with additional data regarding the role of GDF15 and AV-380 in cancer cachexia, are being submitted for publication in a scientific journal.
About AV-380
AV-380 is a potential first-in-class GDF15 inhibitor, discovered using AVEO’s proprietary Human Response Platform™, that provides the company unique insights into cancer and related disease biology. The first-in-human clinical trial of AV-380 is planned for the second half of 2015. Initial clinical development is expected to be for the treatment of cancer cachexia. AVEO plans to evaluate opportunities for partnerships to expand the development of AV-380, including in cachexia associated with non-cancer indications, including chronic heart failure, chronic kidney disease and chronic obstructive pulmonary disease to leverage the full potential of this asset.
About Cachexia
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases, characterized by symptoms of unintentional weight loss, progressive muscle wasting and loss of appetite (anorexia). Cachexia affects some five million individuals in the United States1. It is estimated that 60-80% of patients with advanced cancer have cachexia2,3 and approximately 30% of cancer patients die due to cachexia4.
About AVEO
AVEO Oncology (NASDAQ:AVEO) is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.
References
1 Morley et al. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–43.
2 Tan BHL et al. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008;11(4):400-407.
3 von Haehling S et al. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1–5.
4 Del Fabbro E, Inui A, Strasser F. Cancer Cachexia. Pocket book for cancer supportive care. Springer Healthcare, 2012.
SOURCE: AVEO Oncology
Post Views: 165
MONTREAL, Canada I September 26, 2014 I AVEO Oncology (NASDAQ:AVEO) today announced the presentation of results from four preclinical studies of AV-380, the Company’s potent, humanized inhibitory antibody targeting growth differentiation factor 15 (GDF15), in various in vivo cachexia models and in vitro assays at the 2nd Cancer Cachexia Conference, being held September 26-28, 2014, in Montreal, Canada. In addition to the poster presentations, the AVEO research was selected for presentation in an oral session titled “Targeting GDF15 with the inhibitory antibody AV-380 for the treatment of Cancer Cachexia.”
“These data expand our understanding of the central role that GDF15 may play in the development and progression of cancer cachexia,” said Jeno Gyuris, Ph.D., chief scientific officer of AVEO. “These studies demonstrate that elevated levels of circulating GDF15 drive the development of cancer cachexia in mice, and that its inhibition, with AV-380, completely reversed body weight loss and restored normal body composition, including fat, muscle and organ size. We have also demonstrated that the combination of AV-380, an anti-cachexia agent, with an anti-cancer treatment, dramatically prolonged survival compared to mice treated with anti-cancer therapy alone. We look forward to building on these discoveries as we progress AV-380 toward clinical study, expected to begin in the second half of 2015.”
“Cachexia is a well-recognized unmet medical need associated with multiple chronic disease states, including cancer, and is gaining increasing therapeutic focus, as noted in international scientific meetings such as the concurrent Cancer Cachexia Conference and European Society of Medical Oncology 2014 Congress,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO. “GDF15 may represent an important mechanism to target for therapeutic intervention, a hypothesis supported by selection of AVEO’s data for oral presentation by the Cancer Cachexia Conference.”
Data from these posters, titled “Induction of Cancer Cachexia by Inflammatory Molecules in Directed Complementation Tumor Models;” “Complete reversal of CASC in animal models by AV-380, a GDF15 inhibitory antibody;” “The combination of GDF15 blockade with an anti-cancer agent reverses cachexia and significantly prolongs survival in xenograft models;” and “Recombinant GDF15 does not trigger canonical SMAD2 pathway activation in vitro,” together with additional data regarding the role of GDF15 and AV-380 in cancer cachexia, are being submitted for publication in a scientific journal.
About AV-380
AV-380 is a potential first-in-class GDF15 inhibitor, discovered using AVEO’s proprietary Human Response Platform™, that provides the company unique insights into cancer and related disease biology. The first-in-human clinical trial of AV-380 is planned for the second half of 2015. Initial clinical development is expected to be for the treatment of cancer cachexia. AVEO plans to evaluate opportunities for partnerships to expand the development of AV-380, including in cachexia associated with non-cancer indications, including chronic heart failure, chronic kidney disease and chronic obstructive pulmonary disease to leverage the full potential of this asset.
About Cachexia
Cachexia is a serious and common complication in patients with advanced cancer and other chronic diseases, characterized by symptoms of unintentional weight loss, progressive muscle wasting and loss of appetite (anorexia). Cachexia affects some five million individuals in the United States1. It is estimated that 60-80% of patients with advanced cancer have cachexia2,3 and approximately 30% of cancer patients die due to cachexia4.
About AVEO
AVEO Oncology (NASDAQ:AVEO) is a biopharmaceutical company committed to discovering and developing targeted therapies designed to provide substantial impact in the lives of people with cancer by addressing unmet medical needs. AVEO’s proprietary Human Response Platform™ provides the company unique insights into cancer and related disease biology and is being leveraged in the discovery and clinical development of its therapeutic candidates. For more information, please visit the company’s website at www.aveooncology.com.
References
1 Morley et al. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006;83:735–43.
2 Tan BHL et al. Cachexia: prevalence and impact in medicine. Curr Opin Clin Nutr Metab Care 2008;11(4):400-407.
3 von Haehling S et al. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia Sarcopenia Muscle 2010;1:1–5.
4 Del Fabbro E, Inui A, Strasser F. Cancer Cachexia. Pocket book for cancer supportive care. Springer Healthcare, 2012.
SOURCE: AVEO Oncology
Post Views: 165
